Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03YVO
|
||||
| Former ID |
DNAP001296
|
||||
| Drug Name |
Methylnaltrexone bromide
|
||||
| Synonyms |
Relistor (TN)
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Opioid-induced constipation [ICD9: 564; ICD10:K59.0] | Approved | [1] | ||
| Company |
Progenics
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C21H26BrNO4
|
||||
| Canonical SMILES |
C[N+]1(CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6<br />.[Br-]
|
||||
| InChI |
1S/C21H25NO4.BrH/c1-22(11-12-2-3-12)9-8-20-17-13-4-5-14(23)18(17)26-19(20)15(24)6-7-21(20,25)16(22)10-13;/h4-5,12,16,19,25H,2-3,6-11H2,1H3;1H/t16-,19+,20+,21-,22?;/m1./s1
|
||||
| InChIKey |
IFGIYSGOEZJNBE-KNLJMPJLSA-N
|
||||
| CAS Number |
CAS 73232-52-7
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| SuperDrug ATC ID |
A06AH01
|
||||
| Target and Pathway | |||||
| Target(s) | Mu-type opioid receptor | Target Info | Modulator | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Estrogen signaling pathway | |||||
| Morphine addiction | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Enkephalin release | |||||
| Pathway Interaction Database | IL4-mediated signaling events | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | TCR Signaling Pathway | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Peptide GPCRs | |||||
| Opioid Signalling | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.